跳转至内容
Merck
CN

SML3771

LMTK3 inhibitor C28

≥98% (HPLC)

别名:

6-(4-Pyridinyl)-3-[3-(trifluoromethoxy)phenyl]imidazo[1,2-b]pyridazine, 6-(Pyridin-4-yl)-3-(3-(trifluoromethoxy)phenyl)imidazo[1,2-b]pyridazine

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C18H11F3N4O
化学文摘社编号:
分子量:
356.30
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


Quality Segment

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear (Warmed)

storage temp.

-10 to -25°C

SMILES string

FC(OC1=CC=CC(C2=CN=C3C=CC(C4=CC=NC=C4)=NN32)=C1)(F)F

InChI

1S/C18H11F3N4O/c19-18(20,21)26-14-3-1-2-13(10-14)16-11-23-17-5-4-15(24-25(16)17)12-6-8-22-9-7-12/h1-11H

InChI key

SFBZOJORTROAIE-UHFFFAOYSA-N

Biochem/physiol Actions

Compound C28 is an orally active, potent, ATP-competitive lemur tyrosine kinase 3 (LMTK3) inhibitor with additional inhibitory potency against only 4 other kinases among a panel of 140 (IC50 = 67 nM/LMTK3, 5 nM/CLK, 6 nM/DYRK1α, 48 nM/HIPK2, 41 nM/IRAK4). LMTK3 promotes proteasome-mediated LMTK3 degradation and decreases proliferation of cancer cultures (NCI-60 panel IC50 <10 μM) and displays antitumor efficacy in xenograft and transgenic breast cancer mouse models in vivo (10 mg/mL via dialy p.o.).
Orally active, potent, ATP-competitive lemur tyrosine kinase 3 (LMTK3), CLK, DYRK1α, HIPK2 inhibitor with anticancer efficacy in cultures and in vivo.


存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库